pharm14520240209161306384EMO_en_20240209161306506.png

過去のプログラムはこちら

罫線.png

罫線1

創薬サイエンス_バナーRGB_w250px.gif

創薬サイエンス

7_10051-2：東京大学.jpg

創薬等先端技術支援基盤プラットフォーム

罫線2

第9回精神薬学会バナー500×200.jpg

第9回日本精神薬学会総会・学術集会

第35回日本医療薬学会年会バナー.jpg

第35回日本医療薬学会年会

罫線3

General information

Overview

Announcements(26)

Timetable

Thu. Mar 27, 2025

Fri. Mar 28, 2025

Sat. Mar 29, 2025

Program & Abstract

Sessions

Search presentations

Selected programs of presentations in English

Download Abstracts PDF

Registration

Registration (Non-presenters under 4th year underg

For Participants and Presenters

Participation Certificate PDF

For Participants

For Presenters

How to use "Confit mobile meeting app"

Exhibition

Companies（Equipment exhibits）

Companies（Medical supplies）

Bibliographic information retrieval system

Companies（Books）

Abstract Submission (Oral/Poster Presentation)

Abstract Submission

header_en_20240313161625152.png

app_icon.png

Profile management

Bookmark

Announcements

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Sotorasib function as a pan RAS G12C inhibitor

Cancer is the leading cause of death in Japan. The age-adjusted mortality rate for cancer has been declining for 20 years, and the crude rate has begun to level off. This trend is due to advances in cancer treatment, particularly surgery, radiotherapy and chemotherapy. New treatments, such as molecular targeted therapy and immunotherapy, have transformed cancer care. Many new drugs have been developed over the past two decades, and immune checkpoint inhibitors have been a game changer. These new drugs and combination therapies are becoming standard of care in cancer treatment, and the role of pharmaceutical research and pharmacists has grown significantly.<br />This symposium will focus on pharmaceutical approaches to cancer research, covering topics such as understanding cancer cell characteristics, exploring therapeutic targets, developing new drugs, and analyzing drug resistance, with discussions based on our recent studies. We aim to inspire young researchers and contribute to the revitalization of cancer research by providing insight into these developments. Advances in cancer research require the integration of knowledge and expertise from diverse fields such as biology, biochemistry, pharmaceutical hygiene, pharmacology and pharmacokinetics. It is truly an "all pharmacy" endeavor that requires a comprehensive blend of knowledge, skills and experience.

Pharmacological approaches to therapeutic target discovery and drug resistance in cancer

The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Presentation Information

[S32-4]Sotorasib function as a pan RAS G12C inhibitor

Password required to view